FDA cancels AdCom meeting for DBV’s peanut allergy patch, citing efficacy concerns
An analyst called the patch "dead in the water," also noting that the ongoing Covid-19 pandemic could challenge the rollout of a competing therapy, Aimmune's Palforzia, which the FDA approved in January.
